Crohn’s Disease - Drug Pipeline Landscape, 2023

Crohn’s Disease - Drug Pipeline Landscape, 2023

Crohn’s disease is a type of inflammatory bowel disease and is a chronic disease that causes inflammation, swelling and irritation in digestive tract. Crohn’s disease most commonly occurs in the small intestine and the colon. It can affect any part of your gastrointestinal (GI) tract, from the mouth to the anus.

The exact cause of Crohn’s disease is unknown. Risk factors of developing the condition, including autoimmune disease, genetic causes, and smoking.

Crohn’s disease patients may experience symptoms like diarrhea, fever, fatigue, reduced appetite and weight loss, inflammation of skin, eyes and joints, inflammation of the liver or bile ducts, kidney stones, iron deficiency (anemia).

Diagnosis tests of Crohn’s disease include blood test, stool test, colonscopy, computed tomography CT scan, upper gastrointestinal GI endoscopy, and GI exam.

Treatment of Crohn’s disease include medications like anti-inflammatory drugs, immune system suppressors, biologics, antibiotics and other medications. Nutrition therapy and surgery can also be suggested for the treatment by the healthcare provider.

Report Highlights

Global Insight Service’s, Crohn’s Disease - Drug Pipeline Landscape, 2022 report provides an overview of the Crohn's disease pipeline drugs. This report covers detailed insights on Crohn’s Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Crohn’s Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.